Patents by Inventor Peter L. Toogood

Peter L. Toogood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
    Publication number: 20220388964
    Abstract: The invention provides (aza)indazolyl-aryl sulfonamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting GCN2 activity.
    Type: Application
    Filed: April 13, 2020
    Publication date: December 8, 2022
    Inventors: Savithri Ramurthy, Mark J. Mulvihill, Bradley Sherborne, Eric Talbot, Chris Thomson, Thomas Daniel Aicher, Fernando Padilla, Clarke B. Taylor, Peter L. Toogood
  • DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
    Publication number: 20210139484
    Abstract: The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.
    Type: Application
    Filed: April 11, 2019
    Publication date: May 13, 2021
    Inventors: Thomas Daniel Aicher, Donald J. Skalitzky, Peter L. Toogood, Chad A. Vanhuis
  • INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE
    Publication number: 20200207726
    Abstract: The invention provides aryl indolinyl sulfonamide and related compounds, pharmaceutical compositions, methods of promoting ROR? activity and/or increasing the amount of IL-17 in a subject, and therapeutic uses of the indolinyl sulfonamide and related compounds, such as treating medical conditions in which activation of immune response is beneficial.
    Type: Application
    Filed: September 9, 2019
    Publication date: July 2, 2020
    Inventors: Chad A. VanHuis, Thomas D. Aicher, Peter L. Toogood
  • Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease
    Patent number: 10556898
    Abstract: The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(3-(5-((1H-indazol-5-yl)amino)-1,2,4-thiadiazol-3-yl)phenyl)-heteroaryl-carboxamide compound.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: February 11, 2020
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Fernando Padilla, Donald J. Skalitzky, Peter L. Toogood, Chad A. VanHuis
  • Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
    Patent number: 10532088
    Abstract: The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR?) and provides adoptive cellular therapies using an agonist of ROR?, populations of lymphocyte cells that have been exposed to an agonist of ROR?, populations of dendritic cells that have been exposed to an agonist of ROR?, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of ROR? to a patient.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: January 14, 2020
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Xiao Hu, Thomas D. Aicher, Laura Lee Celeste, Xikui Liu, Clarke B. Taylor, Chad A. Van Huis
  • INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE
    Publication number: 20190276447
    Abstract: The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(3-(5-((1H-indazol-5-yl)amino)-1,2,4-thiadiazol-3-yl)phenyl)-heteroaryl-carboxamide compound.
    Type: Application
    Filed: February 14, 2019
    Publication date: September 12, 2019
    Inventors: Thomas D. Aicher, Fernando Padilla, Donald J. Skalitzky, Peter L. Toogood, Chad A. VanHuis
  • Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
    Patent number: 10377768
    Abstract: The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 13, 2019
    Assignees: Lycera Corporation, Merck Sharp & Dohme Corp.
    Inventors: Thomas D. Aicher, Kenneth J. Barr, Blair T. Lapointe, Vladimir Simov, Karin A. Stein, William D. Thomas, Peter L. Toogood, Chad A. Van Huis, Catherine M. White
  • Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10208061
    Abstract: The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR activity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: February 19, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Peter L. Toogood, Xiao Hu
  • Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease
    Patent number: 10112935
    Abstract: The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(5-[5-[(1H4ndazol-5-yl)amino]-1,3,4-thiadiazol-2-yl]pyridin-3-yl)acetamide compound.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 30, 2018
    Assignee: Lycera Corporation
    Inventors: Thomas Daniel Aicher, Fernando Padilla, Peter L. Toogood, Shoujun Chen
  • Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease
    Publication number: 20180179224
    Abstract: The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting RORy activity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.
    Type: Application
    Filed: October 11, 2017
    Publication date: June 28, 2018
    Inventors: Thomas D. Aicher, Peter L. Toogood, Xiao Hu
  • INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE
    Publication number: 20180093978
    Abstract: The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(5-[5-[(1H4ndazol-5-yl)amino]-1,3,4-thiadiazol-2-yl]pyridin-3-yl)acetamide compound.
    Type: Application
    Filed: February 26, 2016
    Publication date: April 5, 2018
    Inventors: Thomas Daniel Aicher, Fernando Padilla, Peter L. Toogood, Shoujun Chen
  • Indazole guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9920012
    Abstract: The invention provides indazole guanidine compounds that inhibit F1F0-ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: March 20, 2018
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Donald J. Skalitzky, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
  • TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
    Publication number: 20170313722
    Abstract: The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 2, 2017
    Inventors: Thomas D. Aicher, Kenneth J. Barr, Blair T. Lapointe, Vladimir Simov, Karin A. Stein, William D. Thomas, Peter L. Toogood, Chad A. VanHuis, Catherine M. White
  • Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
    Patent number: 9802958
    Abstract: The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: October 31, 2017
    Assignee: LYCERA CORPORATION
    Inventors: Thomas D. Aicher, Peter L. Toogood, Xiao Hu
  • Tetrahydronaphthyridine and related bicyclic compounds for inhibition of ROR? activity and the treatment of disease
    Patent number: 9657033
    Abstract: The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: May 23, 2017
    Assignees: Lycera Corporation, Merck Sharp & Dohme Corp.
    Inventors: Thomas D. Aicher, Kenneth J. Barr, Blair T. Lapointe, Vladimir Simov, Karin A. Stein, William D. Thomas, Peter L. Toogood, Chad A. Van Huis, Catherine M. White
  • Saturated acyl guanidine for inhibition of FF-ATPase
    Patent number: 9580391
    Abstract: The invention provides saturated acyl guanidine compounds that inhibit F1F0-ATPase, and methods of using saturated acyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: February 28, 2017
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
  • Adoptive Cellular Therapy Using an Agonist of Retinoic Acid Receptor-Related Orphan Receptor Gamma & Related Therapeutic Methods
    Publication number: 20170007686
    Abstract: The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR?) and provides adoptive cellular therapies using an agonist of ROR?, populations of lymphocyte cells that have been exposed to an agonist of ROR?, populations of dendritic cells that have been exposed to an agonist of ROR?, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of ROR? to a patient.
    Type: Application
    Filed: February 27, 2015
    Publication date: January 12, 2017
    Inventors: Gary D. Glick, Peter L. Toogood, Xiao Hu, Thomas D. Aicher, Laura Lee Celeste, Xikui Liu, Clarke B. Taylor, Chad A. Van Huis
  • N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ROR? activity and the treatment of disease
    Patent number: 9512111
    Abstract: The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: December 6, 2016
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Arthur G. Romero, Chad A. Van Huis, Thomas D. Aicher, Carl Kaub, Matthew N. Mattson, William D. Thomas, Karin A. Stein, Erik Krogh-Jespersen, Zhan Wang
  • Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease
    Publication number: 20160318951
    Abstract: The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.
    Type: Application
    Filed: July 8, 2016
    Publication date: November 3, 2016
    Inventors: Thomas D. Aicher, Peter L. Toogood, Xiao Hu
  • Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 9394315
    Abstract: The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, increasing the amount of IL-17 in a subject, and treating cancer, bacterial infections, and fungal infections using such tetrahydro[1,8]naphthyridine and related compounds.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: July 19, 2016
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Peter L. Toogood, Xiao Hu